ErbB2-CAR-modified CIK cells exhibited sufficient in-vitro expansion and retained NKG2D-mediated cytotoxicity against ErbB2-negative tumors, whereas ErbB2-CAR CIK cells, but not parental CIK cells, proliferated, infiltrated, and efficiently lysed ErbB2-positive tumor cell monolayers and 3D tumor spheroids in-vitro. The gene discussed is KLRK1; the disease is neoplasm.